Document Detail

Urinary excretion of N-acetyl-beta-D-glucosaminidase and alanine aminopeptidase in patients receiving amikacin or cis-platinum.
MedLine Citation:
PMID:  6113066     Owner:  NLM     Status:  MEDLINE    
Urinary excretion of alanine aminopeptidase (EC and N-acetyl-beta-D-glucosaminidase (EC was determined for 25-70 days in five patients receiving cis-platinum and for 8-53 days in six patients receiving amikacin. This study was performed to investigate if the excretion of urinary enzymes represents a sensitive parameter for the early detection of toxic kidney damage. The determination of N-acetyl-beta-D-glucosaminidase was carried out by the method of Knoll et al. [13]. The procedure of Mondorf et al. [14] for the estimation of alanine aminopeptidase activity was adapted to the Gemsaec Fast-Analyzer. In both patient groups an increase in the excretion of the two enzyme activities could be demonstrated. In patients receiving amikacin, the excretion of alanine aminopeptidase was always higher than that of N-acetyl-beta-D-glucosaminidase, whereas in three patients receiving cis-platinum it was the opposite. In two cis-platinum patients the excretion of both enzymes was of the same size. The changes during amikacin therapy seem to be reversible, whereas in four cis-platinum patients these changes seemed to be partly irreversible. Serum creatinine concentration was less sensitive than the urinary enzyme excretion for detection of kidney damage.
U Diener; E Knoll; B Langer; H Rautenstrauch; D Ratge; H Wisser
Related Documents :
11880876 - Reagent strip diagnosis of uti in a high-risk population.
22353856 - Study on the microbial safety of an infusion set for contrast-enhanced imaging.
8050326 - Polyomavirus in the urine: follow-up study.
25425026 - Manual urine microscopy versus automated urine analyzer microscopy in patients with acu...
22116106 - Assessing abnormal iron content in the deep gray matter of patients with multiple scler...
22836366 - Neurological improvement and prognosis after occipito-thoracic fusion in patients with ...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Clinica chimica acta; international journal of clinical chemistry     Volume:  112     ISSN:  0009-8981     ISO Abbreviation:  Clin. Chim. Acta     Publication Date:  1981 May 
Date Detail:
Created Date:  1981-08-20     Completed Date:  1981-08-20     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  1302422     Medline TA:  Clin Chim Acta     Country:  NETHERLANDS    
Other Details:
Languages:  eng     Pagination:  149-57     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Acetylglucosaminidase / urine*
Amikacin / therapeutic use*
Aminopeptidases / urine*
Antigens, CD13
Cisplatin / therapeutic use*
Creatinine / blood
Hexosaminidases / urine*
Kanamycin / analogs & derivatives*
Kidney / drug effects,  enzymology
Middle Aged
Reference Values
Reg. No./Substance:
15663-27-1/Cisplatin; 37517-28-5/Amikacin; 59-01-8/Kanamycin; 60-27-5/Creatinine; EC 3.2.1.-/Hexosaminidases; EC; EC 3.4.11.-/Aminopeptidases; EC, CD13

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Biological variations in hyperlipidemic children and adolescents treated with fenofibrate.
Next Document:  Measurement of plasma gamma-glutamyltransferase in clinical chemistry: kinetic basis and standardisa...